Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Non-alcoholic Steatohepatitis Treatment Market

Non-alcoholic Steatohepatitis Treatment Market Trends

  • Report ID: GMI10894
  • Published Date: Aug 2024
  • Report Format: PDF

Non-alcoholic Steatohepatitis Treatment Market Trends

The growth of the market is significantly driven by advancements in diagnostic techniques. Innovations in medical technology and diagnostic methods have enhanced healthcare professionals' ability to detect and monitor NASH more accurately and efficiently. These advancements have led to the development of less invasive and more precise diagnostic devices, which are critical for effectively managing the disease. For instance, a report by the American Association for the Study of Liver Diseases (AASLD) highlighted a 40% improvement in the accuracy of non-invasive diagnostic tools between 2010 and 2020.
 

This improvement has enabled the early identification of NASH in many patients, facilitating timely intervention and treatment. These diagnostic advancements have not only raised the standards of NASH care but also significantly increased the number of liver disease diagnoses, thereby driving the demand for effective therapeutic solutions. The improved detection capabilities have encouraged more patients to seek medical advice and treatment, thus contributing to the expansion of the NASH treatment market.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The non-alcoholic steatohepatitis treatment industry size was USD 5.5 billion in 2023 and is expected to showcase 29.9% CAGR from 2024 to 2032 due to increasing prevalence of metabolic disorders

The oral route of administration segment accounted for 63.6% of the market share in 2023 due to several advantages, such as ease of administration, patient compliance, and cost-effectiveness

North America non-alcoholic steatohepatitis treatment industry is expected to reach USD 23.2 billion by 2032 due to serious complications like cirrhosis and liver cancer if left untreated.

AstraZeneca, Bristol-Myers Squibb Company, Conatus Pharmaceuticals, Galmed Pharmaceuticals, Genfit, Gilead Sciences, Inc., Immuron Ltd, and Intercept Pharmaceuticals, Inc.

Non-alcoholic Steatohepatitis Treatment Market Scope

Buy Now


Premium Report Details

  • Base Year: 2023
  • Companies covered: 12
  • Tables & Figures: 282
  • Countries covered: 23
  • Pages: 159
 Download Free Sample